Artwork

Inhoud geleverd door Labiotech. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Labiotech of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Player FM - Podcast-app
Ga offline met de app Player FM !

New class of small molecule therapeutics introduced

26:35
 
Delen
 

Manage episode 385552351 series 3361449
Inhoud geleverd door Labiotech. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Labiotech of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

On this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of the newly-launched U.S. company Gate Bioscience.

00:45-01:06: About Gate Bioscience
01:06-02:09: What are disease-causing extracellular proteins?
02:09-04:44: How have diseases caused by extracellular proteins been treated in the past?
04:44-05:47: Have there been diseases that haven’t been addressed?
05:47-07:05: Tackling the different issues created by extracellular proteins
07:05-09:41: What are molecular gates?
09:41-12:56: How does your technique distinguish between good and bad extracellular proteins?
12:56-16:24: How did the idea become a company?
16:24-17:24: Which diseases will you focus on?
17:24-18;47: How do you address costs?
18:47-19:11: How will this be given to patients?
19:11-20:01: Disease cure or disease management?
20:01-21:35: How was the company created?
21:35-24:18: The rise of small molecules
24:18-25:58: What are the next steps?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Hoofdstukken

1. New class of small molecule therapeutics introduced (00:00:00)

2. About Gate Bioscience
 (00:00:45)

3. What are disease-causing extracellular proteins? (00:01:06)

4. How have diseases caused by extracellular proteins been treated in the past?
 (00:02:09)

5. Have there been diseases that haven’t been addressed?
 (00:04:44)

6. Tackling the different issues created by extracellular proteins
 (00:05:47)

7. What are molecular gates?
 (00:07:05)

8. How to distinguish between good and bad extracellular proteins
 (00:09:41)

9. How did the idea become a company?
 (00:12:56)

10. Which diseases will you focus on?
 (00:16:24)

11. How do you address costs? (00:17:24)

12. How will this be given to patients? (00:18:47)

13. Disease cure or disease management? (00:19:11)

14. How was Gate created?
 (00:20:01)

15. The rise of small molecules
 (00:21:35)

16. What are the next steps for Gate Bioscience?
 (00:24:18)

123 afleveringen

Artwork
iconDelen
 
Manage episode 385552351 series 3361449
Inhoud geleverd door Labiotech. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Labiotech of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

On this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of the newly-launched U.S. company Gate Bioscience.

00:45-01:06: About Gate Bioscience
01:06-02:09: What are disease-causing extracellular proteins?
02:09-04:44: How have diseases caused by extracellular proteins been treated in the past?
04:44-05:47: Have there been diseases that haven’t been addressed?
05:47-07:05: Tackling the different issues created by extracellular proteins
07:05-09:41: What are molecular gates?
09:41-12:56: How does your technique distinguish between good and bad extracellular proteins?
12:56-16:24: How did the idea become a company?
16:24-17:24: Which diseases will you focus on?
17:24-18;47: How do you address costs?
18:47-19:11: How will this be given to patients?
19:11-20:01: Disease cure or disease management?
20:01-21:35: How was the company created?
21:35-24:18: The rise of small molecules
24:18-25:58: What are the next steps?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

Hoofdstukken

1. New class of small molecule therapeutics introduced (00:00:00)

2. About Gate Bioscience
 (00:00:45)

3. What are disease-causing extracellular proteins? (00:01:06)

4. How have diseases caused by extracellular proteins been treated in the past?
 (00:02:09)

5. Have there been diseases that haven’t been addressed?
 (00:04:44)

6. Tackling the different issues created by extracellular proteins
 (00:05:47)

7. What are molecular gates?
 (00:07:05)

8. How to distinguish between good and bad extracellular proteins
 (00:09:41)

9. How did the idea become a company?
 (00:12:56)

10. Which diseases will you focus on?
 (00:16:24)

11. How do you address costs? (00:17:24)

12. How will this be given to patients? (00:18:47)

13. Disease cure or disease management? (00:19:11)

14. How was Gate created?
 (00:20:01)

15. The rise of small molecules
 (00:21:35)

16. What are the next steps for Gate Bioscience?
 (00:24:18)

123 afleveringen

Alle afleveringen

×
 
Loading …

Welkom op Player FM!

Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.

 

Korte handleiding